

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report: April 7, 2020



TECOGEN INC. (NASDAQ: TGEN)
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-36103
(Commission File Number)

04-3536131
(IRS Employer Identification No.)

45 First Avenue
Waltham, Massachusetts
(Address of Principal Executive Offices)

02451
(Zip Code)

(781) 466-6400
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, \$.001 par value per share	TGEN	NASDAQ

Item 7.01. Regulation FD Disclosure.

On April 7, 2020 John N. Hatsopoulos, Lead Director of Tecogen, Inc., circulated a letter to shareholders relating to the company's response to the coronavirus pandemic. A copy of the letter from Mr. Hatsopoulos is being furnished as Exhibit 99.01 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.01 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:

<u>Exhibit</u>	<u>Description</u>
99.01	Letter to Shareholders dated April 7, 2020 from John N. Hatsopoulos

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

TECOGEN INC.

April 7, 2020

By: /s/ Benjamin Locke
Benjamin Locke, Chief Executive Officer



April 7, 2020

Dear Friends and Shareholders:

I write to provide whatever comfort I can in the midst of the Coronavirus pandemic and the turmoil it has brought to us all, including our families, our home and work lives, and the economy and markets. I am sure that you are aware of the negative impact of the pandemic on market investments, including our investments in Tecogen Inc. As you know, between my family and my brother's family (and family trusts), our interests represent a significant part of Tecogen's equity as well as an important part of our families' investments, and I want to assure you that, together with the company, I am working to preserve and grow Tecogen's value.

We have been working hard to maintain Tecogen's operations to the extent possible during the current pandemic despite widespread stay-at-home orders. Tecogen is operating as an essential service under state orders where we have operations and customers, and we are maintaining our key manufacturing and service functions and, where possible, have moved less critical functions to home based work. I encourage you to hear the recent comments of Ben Locke and Bob Panora, Tecogen's CEO and President, during an investor conference call on April 1st in which Ben described the impact of the coronavirus on the company and how the company continues to function effectively. The conference call was recorded and can be heard through April 15th by calling 877-660-6853 within the US and Canada, or (201) 612-7415 from other non US locations. The conference call ID # is: 13672659.

Many of you are familiar with the situations in which unusual events negatively impact market values, and know that strong companies survive difficult times and that markets tend to reflect true values over time. I have experienced and benefitted from numerous opportunities when negative market pressures have created good investment opportunities. This was the case at Thermo Electron and its spin-outs, and I believe it will be the case for Tecogen. Please call me at (781) 577-0251 if you would like to discuss my thoughts further.

Be well and thank you.

Sincerely,

A handwritten signature in black ink, appearing to read "John N. Hatsopoulos", with a long horizontal flourish extending to the right.

John N. Hatsopoulos
Lead Director

Tecogen Inc.

45 First Avenue, Waltham, MA 02451 • ph: 781-466-6400 • fax: 781-466-6466 • www.tecogen.com
